Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 111 results for thyroid

  1. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

  2. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  3. What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving long-term health outcomes for people with subclinical hyperthyroidism?

    subclinical hyperthyroidism is persistent and appears to be caused by intrinsic thyroid disease. However, the committee noted that there...

  4. Selumetinib for treating differentiated thyroid cancer [ID1079]

    Discontinued Reference number: GID-TA10207

  5. Minimally invasive video‑assisted parathyroidectomy (HTG350)

    Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.

  6. Hypertension in adults (QS28)

    This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.

  7. Cost saving guidance

    reduction in surgical interventions. Capacity savings: £5,100 Guideline on thyroid disease: assessment and management (NG145) Savings...

  8. Heavy menstrual bleeding: assessment and management (NG88)

    This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

  9. Are there subgroups of people with Graves' disease who have a particularly good response to antithyroid drugs?

    long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...

  10. What is the clinical and cost effectiveness of dosimetry-guided radioactive iodine strategies for hyperthyroidism?

    long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...

  11. What is the long-term clinical and cost effectiveness, including safety, of radioactive iodine for hyperthyroidism?

    long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...

  12. Implantation of an opaque intraocular lens for intractable double vision (HTG185)

    Evidence-based recommendations on implantation of an opaque intraocular lens for intractable double vision. This involves replacing the clear lens of one eye with a non-transparent one to block out one of the double images.

  13. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued Reference number: GID-TA11259

  14. Further research should report details of patient selection, nodule size and position, and whether the nodule is cystic.

    the safety of high-intensity focused ultrasound for symptomatic benign thyroid nodules raises no major safety concerns, however the...